Conference Coverage: ASCO 2025 – Focus on Breast Cancer
Expert perspectives on the latest therapeutic developments, treatment approaches, and implications for clinical decision-making coming out of the ASCO 2025 conference
June 10, 2025
FACULTY CHAIR
Adam Brufsky, MD, PhD, FACP
UPMC Hillman Cancer Center, Pittsburgh, PA, USA
FACULTY MEMBERS
Mark Pegram, MD
Stanford University School of Medicine, Stanford, CA, USA
Hope Rugo, MD, FASCO
University of California, San Francisco, CA, USA
Joyce O’Shaughnessy, MD
Baylor University Medical Center, Dallas, TX, USA
Sara Tolaney, MD, MPH
Dana-Farber Cancer Institute, Boston, MA, USA
Nadia Harbeck, MD, PhD
Ludwig Maximilian University of Munich, Germany
Javier Cortés, MD, PhD
International Breast Cancer Center, Barcelona, Spain
KEY TAKEAWAYS AND STRATEGIC INSIGHTS
- New and Emerging Treatments in HER2+ Metastatic Breast Cancer (mBC)
- New and Emerging Approaches in HR+, HER2– Early BC
- New and Emerging Approaches in HR+, HER2– mBC
- Advances in Early Triple-Negative Breast Cancer (TNBC)
- Advances in mTNBC
